CPT® Code 90624

Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use

The CPT® Code 90624 refers to a specific meningococcal pentavalent vaccine designed to provide active, long-term immunity against meningococcal disease. This vaccine works by exposing the recipient's immune system to altered versions of the pathogens responsible for the disease, prompting the immune system to produce its own antibodies. The body retains a memory of how to generate these antibodies, allowing for a quicker and more effective response upon subsequent exposures to the antigens. Meningococcal disease, while rare, poses a significant health risk as it can lead to severe infections affecting the brain, spinal cord, and bloodstream. The disease can progress rapidly, often within 24 hours, and is particularly prevalent among teenagers and young adults. The vaccine itself comprises two sterile components: the pentavalent MenACWY vaccine, which includes equal amounts of polysaccharides conjugated to a diphtheria toxoid carrier to enhance the immune response, and the MenB-4C component, which typically contains multiple recombinant proteins such as neisserial adhesin A (NadA), factor H binding protein (FHbp), and neisserial heparin binding antigen (NhbA), along with outer membrane vesicles derived from serogroup B meningococcal bacteria. It is important to note that this code specifically reports the vaccine product used and does not encompass the administration of the vaccine itself.